Arrayjet Limited - Industry Context Analysis

1. Industry Classification

Sector: Special-Purpose Machinery Manufacturing (SIC 28990) Sub-sector: Life Science Instrumentation & Microarray Technology

Arrayjet operates within the specialised niche of microarray printing instruments and precision dispensing systems for life science workflows. This positions the company at the intersection of UK manufacturing (SIC 28990) and the global life science tools market—a sector typically characterised by high R&D intensity, long sales cycles, and dependence on institutional procurement budgets (academic institutions, pharmaceutical companies, and government-funded research bodies).

The UK special-purpose machinery manufacturing sector comprises approximately 4,500 enterprises, predominantly SMEs, with combined annual turnover of around £8-10 billion. Companies in this space typically exhibit asset-heavy balance sheets, moderate working capital requirements, and revenue streams that are lumpy due to the capital equipment nature of sales.

2. Relative Performance

Balance Sheet Deterioration: Arrayjet's financial position has weakened materially between FY2024 and FY2025:

Against Industry Benchmarks:

• Current Ratio: Arrayjet's current ratio has fallen to approximately 1.06x (current assets of £1,693,083 ÷ current liabilities of £1,599,834), which is below the typical 1.5-2.0x range considered healthy for capital equipment manufacturers. This suggests tight working capital headroom.

• Cash Conversion: The 55% increase in debtors alongside a 62% decline in cash is a concerning signal. For UK special-purpose machinery companies, debtor days of 60-90 days are typical; the significant debtor build suggests either extended payment terms to secure orders or collection difficulties—both warning signs in this sector.

• Accumulated Losses: The P&L reserve stands at (£4,953,262), indicating sustained historical losses. With share capital and premium totalling £5,218,795 against net assets of only £265,533, the company has consumed approximately 95% of its equity base—a position that would concern trade creditors and lenders.

• Employee Reduction: Headcount fell from 29 to 25 (a 14% reduction), consistent with the stated cost-cutting measures but also indicative of reduced operational capacity.

For context, successful UK life science instrumentation companies typically maintain net margins of 8-15% and current ratios above 1.5x. Arrayjet appears to be performing well below these norms.

3. Sector Trends Impact

Global Life Science Tools Market Headwinds: The directors explicitly reference several macro factors affecting the business, and these align with documented industry challenges:

• NIH/FDA Restructuring: The US National Institutes of Health is the world's largest public funder of biomedical research (approximately $47 billion annually). Any restructuring or budget uncertainty at NIH directly impacts grant-funded equipment purchases. The life science tools sector saw similar disruption during the 2013 US government sequestration, which caused a 12-18 month demand deferral across the industry.

• Tariff Uncertainty: For UK-based manufacturers exporting to the US and EU, evolving tariff regimes create pricing uncertainty and can defer purchasing decisions. Arrayjet's international customer base makes this particularly relevant.

• Post-Pandemic Normalisation: The life science tools sector experienced a demand surge during COVID-19 (2020-2022), followed by a pronounced inventory correction in 2023-2024. Major players like Agilent, Danaher, and Revvity all reported revenue declines of 5-15% through 2024 as customers worked through pandemic-era stockpiles.

UK Manufacturing Context: - UK manufacturing output contracted by approximately 0.5% in 2024, with capital goods sub-sectors particularly affected by weak investment appetite - Sterling volatility against the dollar impacts export competitiveness for UK-based instrumentation manufacturers - R&D expenditure relief changes under the full expensing regime may partially offset, but benefits lag operational pressures

Sector-Specific Dynamics: The microarray market specifically faces structural questions as next-generation sequencing (NGS) costs continue to decline, though microarray technology retains relevance in high-throughput screening applications and diagnostics development. The precision dispensing systems market has broader appeal across liquid handling workflows and represents a defensible niche.

4. Competitive Positioning

Market Position: Niche Player with Specialised Technology

Arrayjet occupies a niche position within the life science instrumentation market. The microarray printing segment is dominated by larger players including: - Agilent Technologies (SpotArray platform, multi-billion dollar revenue) - Inkjet/spotted microarray subsidiaries of major life science conglomerates - Specialist competitors such as Scienion (now part of Cellink/Bico) and Arrayit

As a £1.8 million turnover company (inferred from asset base and sector norms), Arrayjet is significantly sub-scale relative to these competitors. The typical minimum efficient scale for sustainable life science instrument companies is generally considered to be £5-10 million in annual revenue.

Strengths: - Proprietary Technology: 25-year operating history (incorporated 2000) and patent portfolio (£115,858 in intangible assets) suggests defensible IP - Established Market Presence: Longevity in the sector provides installed base and customer relationships - Parent Company Backing: 75%+ ownership by Arrayjet Holdings Ltd provides potential access to group resources - Product Diversification: Precision dispensing systems offer applications beyond microarrays, reducing single-market dependency

Weaknesses: - Critical Financial Fragility: Net current assets of only £93,249 against current liabilities of £1.6 million leaves minimal margin for operational disruption - Cash Burn Trajectory: Cash declined by £272,728 in the year, and at this rate would be exhausted within 7-8 months without revenue recovery or additional funding - Material Going Concern Uncertainty: The explicit disclosure of "material uncertainty over revenue generation and cash inflows" is a significant red flag. Under FRS 102, such disclosures typically indicate the company has narrowly met going concern criteria - Debtor Concentration Risk: The 55% increase in debtors may indicate over-reliance on a small number of large contracts, which is common in capital equipment businesses but creates collection risk - R&D Constraint: The stated limitation on R&D spending is strategically concerning for a technology-dependent company; competitors in this space typically invest 10-15% of revenue in R&D

Competitive Comparison: Against typical sector norms for UK special-purpose machinery manufacturers:

Arrayjet sits at the stressed end of sector norms across virtually all financial metrics. The company's position is not atypical for a sub-scale niche manufacturer navigating a cyclical downturn, but the depth of balance sheet deterioration creates vulnerability to any further revenue deferral.